Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.34 |
| ▸ | BMX | P51813 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18701283 | 0.87 | RAB9A (0.36) | HPGDALDH1A1KDM4ESMN1; SMN2POLB | |
| SCHEMBL22662127 | 0.83 | ALDH1A1 (0.40) | FLT3BMXHPGDALDH1A1KDM4E | |
| SCHEMBL18701353 | 0.83 | ESR1 (0.34) | HPGDALDH1A1KDM4ESMN1; SMN2POLB | |
| SCHEMBL22662208 | 0.82 | ESR1 (0.39) | HPGDALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL20697966 | 0.82 | KDM4E (0.35) | HPGDALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL20697965 | 0.82 | KDM4E (0.35) | HPGDALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL22929890 | 0.81 | KDM4E (0.32) | FLT3BMXALDH1A1KDM4ETP53 | |
| SCHEMBL22662182 | 0.80 | ALDH1A1 (0.40) | HPGDALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL24120818 | 0.80 | ALDH1A1 (0.32) | HPGDALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL20735401 | 0.79 | KDM4E (0.35) | FLT3BMXHPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11322691-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2022-05-03 | — | — | US | disclosed |
| US-20190036031-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11322691-B2 | Organic electroluminescent materials and devices | CTCF, AZI2, CACNA2D2 | FLT3 990/4885BMX 3012/4885HPGD 1815/4885 |
| US-20190036031-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | CTCF, CACNA2D2, PPA1 | FLT3 1330/4885BMX 2523/4885HPGD 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.